Core Insights - Haleon is investing £65 million in a new oral health manufacturing plant in Shanghai to enhance its presence in China's gum health market, which is valued at approximately £860 million [1] - The company aims to expand its gum health brand parodontax to 30 cities in China by the end of 2027, targeting a rising middle class with increasing disposable income [1] - Haleon's investment reflects its long-term commitment to improving the health and wellbeing of Chinese consumers through locally tailored products and enhanced manufacturing capabilities [1] Investment and Expansion - The new manufacturing facility will support the expansion of Haleon's oral care portfolio, including global brands like Sensodyne and parodontax, into tier 2 and tier 3 cities in China [1] - Haleon plans to reach over 250 million people through its distribution strategy, which includes e-commerce platforms and retail pharmacies [1] - The investment is part of a broader strategy to respond quickly to evolving consumer preferences and accelerate innovation in the oral care category [1] Product Development - parodontax is the first clinically proven toothpaste in China targeting the root cause of bleeding gums, with a unique sensory profile adapted for local consumers [1] - Haleon's global R&D team collaborated with local scientists to modify the product's flavor and packaging to better appeal to Chinese consumers [1] - The company is focused on delivering high-quality, science-backed products that align with the growing demand for preventative oral care solutions [1] Strategic Priorities - China is identified as a strategic priority for Haleon, with the company aiming to combine global research expertise with local insights to enhance product offerings [1] - The new facility in Shanghai's Lingang New Area will enable Haleon to build a more agile and efficient supply chain, supporting its ambition to reach one billion more consumers by 2030 [1] - Haleon completed the acquisition of its TSKF joint venture in June 2025, further solidifying its position in China's consumer healthcare market [1]

Core Insights - Haleon is intensifying its expansion in China, focusing on second- and third-tier cities and customizing its gum-health products to local preferences, aiming to succeed where many Western brands have struggled [1] Company Strategy - Haleon is investing £65 million ($87 million) in a new oral-health factory in Shanghai to support its growth strategy in China [1] - The company aims to expand its Parodontax brand into over 30 cities by the end of 2027, addressing a significant consumer need as over 70% of Chinese consumers suffer from gum health issues [1][1] Market Context - China represents about 10% of Haleon's £11 billion business and nearly 13% of the $59 billion global oral-health market, which is projected to reach approximately $80 billion by 2031 [1] - Haleon's Sensodyne toothpaste is experiencing mid-teens growth, with around 11% of Chinese households using the brand, compared to local leader Yunnan Baiyao at 29.8% [1] Product Adaptation - The Parodontax brand was relaunched in China with modifications to suit local tastes, including a sweeter flavor, foamier texture, and glossier packaging, now available in 10,000 outlets across 19 cities [1][1] Competitive Landscape - Many Western companies, such as Starbucks and Nike, are scaling back their operations in China due to weak sales, while Haleon has taken a different approach by buying out the Chinese government from its local joint venture for approximately £700 million [1]

Core Insights - Haleon plc reported Q4 2025 earnings with an EPS of $0.259, surpassing analyst expectations of $0.251, but revenue was approximately $7.52 billion, slightly below the forecast of $7.57 billion [1] Financial Performance - The company achieved an organic growth rate of 3% for the year, falling short of its medium-term target of 4-6%, primarily due to challenges in the North American market, which constitutes 35% of its revenues [2] - North America experienced a 0.4% decline in organic growth, influenced by cautious consumer behavior amid inflation and labor market concerns, particularly affecting discretionary categories like Smokers' Health and multivitamins [2] - Despite these challenges, Haleon reported double-digit profit growth and strong cash generation, indicating robust long-term prospects [2] Valuation Metrics - Haleon's price-to-earnings (P/E) ratio is approximately 14.47, reflecting the market's valuation of its earnings [3] - The price-to-sales ratio stands at about 2.10, indicating the company's market value relative to its sales [3] - The enterprise value to sales ratio is around 2.57, providing a comparison of the company's total value to its sales [3] - The enterprise value to operating cash flow ratio is approximately 37.62, highlighting cash flow generation relative to valuation [3] - The earnings yield is about 6.91%, offering insight into the return on investment [3] - Haleon maintains a moderate leverage level with a debt-to-equity ratio of 0.53 [3] - A current ratio of approximately 0.87 indicates the company's short-term liquidity position [3]

Core Insights - Haleon made significant progress in 2025 against its three strategic priorities: competitive growth, productivity gains, and an agile performance-focused culture [1] - The company achieved 3% organic sales growth in 2025, which is below the medium-term guidance of 4% to 6%, primarily due to lower category growth and decreased consumer confidence in key markets [1] Growth Performance - Despite the challenging environment, 60% of Haleon's brand portfolio gained or maintained market share, indicating strong performance relative to global categories [2] - In China, the launch of parodontax is closing the incident versus treatment gap, with the product becoming a top-selling innovation in major cities and available in over 10,000 stores [2] Product Innovation - The rollout of parodontax will accelerate to 20 cities in 2025 to enhance market penetration [3] - Sensodyne's expanded clinical range has seen strong uptake among younger consumers, with growth exceeding 1.5 times the overall category in 30 global markets [3] - The company is also focusing on innovation-led premiumization, exemplified by the launch of Nasal Mist in North America [3]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 3% for 2025, which was below expectations due to a slowdown in the U.S. market and a weaker cold and flu season [8][9] - Gross margin improved by 220 basis points, contributing to a high single-digit operating growth at constant currency [10][44] - The company anticipates organic sales growth guidance of 3%-5% for 2026, indicating a potential sequential acceleration [6][11] Business Line Data and Key Metrics Changes - The U.S. market experienced a decline of approximately 0.5%, while APAC, EMEA, and LATAM grew in the mid-single digits [8][9] - Oral health business showed strong performance, helping to offset declines in the cold and flu category [9][20] - The company plans to focus on driving category growth through investments in advertising and promotion (A&P) and innovation [10][12] Market Data and Key Metrics Changes - Emerging markets, particularly India and China, are expected to contribute significantly to growth, with India showing double-digit growth and strong performance in oral health [29][30] - The company noted a slowdown in LATAM, particularly in Q4, due to challenging macroeconomic conditions [30][31] - E-commerce is growing aggressively in China, with significant contributions from platforms like Douyin [29][30] Company Strategy and Development Direction - The company has restructured its leadership to enhance agility and drive growth, including the creation of a Chief Growth Officer role and six operating units [15][18] - Focus on innovation and commercial execution is emphasized to improve competitiveness in the U.S. market [15][19] - The company aims to leverage its strengths in oral health and expand its reach in emerging markets [12][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain market conditions but expressed confidence in returning to the medium-term growth target of 4%-6% [11][68] - The company is focused on addressing consumer needs and driving category growth despite current challenges [52][53] - Management highlighted the importance of the cold and flu category for overall consumer health and its role in securing shelf space [56][57] Other Important Information - The company has increased A&P investment by over 7% compared to the previous year, with a significant portion allocated to oral health and emerging markets [35][75] - The productivity program has been successful, allowing for flexibility in investments for growth [44][46] Q&A Session Summary Question: What are the main drivers behind the organic sales growth guidance of 3%-5% for 2026? - Management indicated that the guidance reflects expected market improvements and a focus on driving category growth through investments and innovation [6][11] Question: Can you discuss the new reorganization and its impact on growth in the U.S.? - The reorganization aims to unlock growth and agility, with a focus on commercial execution and category strategies [15][18] Question: How is the performance in emerging markets, and what are the growth drivers? - Emerging markets are performing well, particularly in India and China, with a focus on volume growth and expanding reach [29][30] Question: How does the company plan to balance top-line performance with margin improvement? - Management emphasized the importance of investing in the right areas to drive sustainable growth while improving margins [35][36] Question: What is the outlook for the cold and flu business and its importance? - The cold and flu category is crucial for consumer health and shelf space, with management confident in its long-term growth potential [56][57]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 3% for 2025, which was below expectations due to a slowdown in the U.S. market and a weaker cold and flu season [8][9] - Gross margin improved by 220 basis points, contributing to high single-digit operating growth at constant currency [10][44] - The company anticipates organic sales growth guidance of 3%-5% for 2026, indicating a potential sequential acceleration [6][11] Business Line Data and Key Metrics Changes - The U.S. market experienced a decline of approximately 0.5%, while APAC and EMEA LatAm grew in the mid-single digits [8] - Oral health business showed strong performance, helping to offset declines in the cold and flu category [9][20] - The company plans to focus on driving category growth through investments in advertising and promotion (A&P) and innovation [10][12] Market Data and Key Metrics Changes - Emerging markets, particularly India and China, are expected to contribute significantly to growth, with India showing double-digit growth and strong performance in oral health [29][31] - The company noted a slowdown in LATAM, particularly in Q4, due to challenging macroeconomic conditions [30] - E-commerce is growing rapidly in China, with online sales accounting for around 40% of the business [29] Company Strategy and Development Direction - The company has restructured its leadership to enhance agility and drive growth, creating roles such as Chief Growth Officer and Chief Transformation Officer [15][18] - A focus on unlocking growth through streamlined operations and improved commercial execution is emphasized [15][17] - The company aims to invest in innovation and capabilities while maintaining a leaner organizational structure [18][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in the U.S. market in 2026, despite current challenges [9][12] - The company acknowledges the uncertain market environment but remains optimistic about long-term growth potential in attractive categories [12][68] - Management highlighted the importance of cold and flu products in the overall portfolio and their role in driving consumer health [56] Other Important Information - The company is focusing on improving its supply chain efficiency, which has contributed to gross margin improvements [44][46] - A significant portion of A&P investment is directed towards oral health and emerging markets, reflecting strategic priorities [75] Q&A Session Summary Question: What are the main drivers behind the organic sales growth guidance of 3%-5% for 2026? - Management indicated that the guidance reflects expectations of market improvement and a focus on driving category growth through investments and innovation [6][11] Question: Can you discuss the new reorganization and its impact on growth in the U.S.? - The reorganization aims to enhance agility and streamline operations, with new leadership roles expected to drive volume growth and innovation [15][18] Question: How is the performance in emerging markets, and what areas are underperforming? - Emerging markets are performing well, particularly in India, while LATAM has faced challenges due to macroeconomic conditions [30][31] Question: How does the company plan to balance top-line performance with margin improvement? - Management emphasized the importance of investing in growth while achieving margin improvements through supply chain efficiencies [35][44] Question: What is the outlook for the cold and flu business and its importance in securing shelf space? - The cold and flu category is considered crucial for consumer health, and management believes it will play an important role in future growth [56]

Financial Data and Key Metrics Changes - The company reported organic sales growth of 3% for 2025, which was below expectations due to a slowdown in the U.S. market and a weaker cold and flu season [6][10] - Gross margin improved by 220 basis points, contributing to high single-digit operating growth at constant currency [9][43] - The company anticipates organic sales growth guidance of 3%-5% for 2026, indicating a potential sequential acceleration [5][10] Business Line Data and Key Metrics Changes - The U.S. market experienced a decline of approximately 0.5%, while APAC and EMEA LatAm grew in mid-single digits [6][10] - Oral health business showed strong performance, helping to offset declines in the cold and flu category [7][18] - The productivity program continues to deliver efficiencies, allowing for investment in growth despite challenges in other categories [9][43] Market Data and Key Metrics Changes - Emerging markets, particularly India and China, are expected to drive growth, with India showing double-digit growth and strong performance in oral health [26][27] - The company noted a slowdown in LATAM and EMEA due to challenging macro conditions, particularly in the fourth quarter [28][29] - E-commerce in China is growing rapidly, with significant contributions from platforms like Douyin [27] Company Strategy and Development Direction - The company is focused on unlocking growth through a new organizational structure, including the creation of a Chief Growth Officer role and six operating units [14][16] - Investment in advertising and promotion (A&P) is prioritized, with half of the increase directed towards oral health and emerging markets [73] - The strategy emphasizes innovation and category growth, particularly in oral health and addressing low-income consumer needs [11][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in the U.S. market in 2026, despite current challenges [11][66] - The company acknowledges the uncertain market environment but remains optimistic about the potential for recovery and growth in emerging markets [11][66] - Management highlighted the importance of cold and flu products in the overall portfolio and their role in driving consumer health [56] Other Important Information - The company is implementing a productivity program aimed at reducing complexity in the supply chain, which has already shown positive results [43][45] - The company is addressing challenges in specific brands, such as Nexium in the digestive health category, while also focusing on opportunities related to GLP-1 medications [60][62] Q&A Session Questions and Answers Question: What will be the main drivers behind the organic sales growth guidance of 3%-5% for 2026? - Management indicated that the guidance reflects expected improvements in market conditions and competitive performance, with a focus on driving category growth and innovation [5][10] Question: Can you discuss the new reorganization and its impact on growth in the U.S.? - The reorganization aims to streamline operations and enhance agility, with new leadership roles expected to drive volume growth and innovation [14][16] Question: How is the company addressing the slowdown in emerging markets? - Management expressed excitement about emerging markets, particularly in Asia PAC, where growth is driven by volume mix and expanding reach among lower-income consumers [26][29] Question: What is the company's strategy for improving volume growth? - The company is focused on a balanced price-volume mix and has implemented key actions to drive volume growth, particularly in North America [36][37] Question: How important is the cold and flu business for securing shelf space? - Management emphasized the significance of the cold and flu category for consumer health and its role in category management, despite recent declines [56]

Core Viewpoint - Haleon anticipates a challenging cold and flu season in Q1 2026, with expectations for organic sales growth of 3%–5% in 2026, driven by improved competitiveness and category growth initiatives [1][2][4]. Financial Performance - Haleon reported 2025 organic sales growth of 3%, below the medium-term target of 4%–6%, primarily due to a milder cold and flu season and weak consumer confidence [6][7]. - The company achieved a gross margin improvement of 220 basis points and generated £1.9 billion in free cash flow, supported by an ongoing £800 million productivity program [5][18]. - A £500 million buyback allocation and a 7.6% increase in the full-year dividend to 7.1p were announced [4]. Market Outlook - The U.S. market is expected to return to growth in 2026, with inventory levels now deemed appropriate [2]. - Haleon is focusing on driving category growth through increased investment in advertising and promotion, innovation, and a new operating model [2][8]. Strategic Initiatives - A new chief growth officer role has been created to enhance marketing capabilities and commercial execution, with a shift from three regions to six operating units [8][9]. - The company is implementing AI-driven tools for net revenue management and pricing actions, aiming for a flatter organizational structure [9][10]. Brand and Category Performance - Oral health products, particularly Sensodyne and parodontax, are performing well, with significant growth in emerging markets like India and China [13][14]. - Haleon is addressing opportunities in digestive health and pain relief, with brands like TUMS and Voltaren showing strong market positions [16][17]. Investment and Growth Focus - Haleon increased advertising and promotion spending by 7.5% and R&D by 7.7% in 2025, emphasizing sustainable growth investments [19]. - The company is focused on maintaining a strong working/non-working media split, with 60% of working media allocated to digital channels [19].

Financial Data and Key Metrics Changes - In 2025, the company achieved 3% organic sales growth, which is below the medium-term guidance of 4%-6% due to lower category growth and reduced consumer confidence in key markets [1][5] - Full year organic revenue growth was 3%, with a split of 2.3% from price and 0.7% from volume mix [11] - Gross margin improved by 220 basis points, resulting in 10.5% organic profit growth [6][10] - Free cash flow reached GBP 1.9 billion, with a reduction in working capital by 11 days [10][22] Business Line Data and Key Metrics Changes - Oral health delivered high single-digit growth, outperforming the market with a 7.9% increase, driven by brands like Sensodyne and parodontax [13][20] - VMS (Vitamins, Minerals, and Supplements) grew 1.9%, with strong performance outside the U.S. but impacted by a softer multivitamin category in North America [14][17] - OTC (Over-the-Counter) pain relief grew 2.3%, with notable growth from Panadol and Advil [14][16] - Respiratory health declined by 1.9%, affected by a challenging consumer environment and a weaker cold and flu season [16] Market Data and Key Metrics Changes - North America experienced a 0.4% decline in organic revenue, with a split of 1% price increase and a 1.4% decline in volume mix [17] - EMEA and Latin America saw organic revenue increase by 4.7%, driven by price and volume mix [19] - Asia Pacific reported a 5.2% organic revenue growth, with significant contributions from China and India [20] Company Strategy and Development Direction - The company is focused on three strategic priorities: delivering competitive growth, unlocking productivity gains, and embedding an agile culture [1][4] - A new operating model is being implemented to enhance growth and agility, including the creation of new leadership roles and operating units [28][29] - The company plans to invest in A&P (Advertising and Promotion) and R&D to drive innovation and market execution [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning North America to growth, despite a challenging operating environment [7][32] - The outlook for 2026 anticipates organic revenue growth of 3%-5%, with continued strength in emerging markets [25][26] - Management acknowledged the need for improved organic revenue performance and is focused on unlocking productivity to drive growth [10][26] Other Important Information - The company allocated GBP 500 million for share buybacks in 2026 and proposed a final dividend of 4.9 pence, reflecting a 7.6% increase in total dividends for the year [6][25] - The productivity agenda aims for a reduction of SKUs and packaging by around 30% over three years, with expected gross annualized savings of GBP 175 million to GBP 200 million [4][24] Q&A Session Summary Question: What are the expectations for North America returning to growth? - Management is implementing a broader action plan and has strengthened the North America team to drive growth through improved marketing effectiveness and innovation [32] Question: How is the company addressing the challenges in the U.S. market? - The company is focusing on scaling innovations faster and leveraging its portfolio to improve competitive positioning in key categories [32]

Financial Data and Key Metrics Changes - In 2025, the company achieved 3% organic sales growth, which is below the medium-term guidance of 4%-6% due to lower category growth and reduced consumer confidence in key markets [1][5] - Full year organic revenue growth was 3%, with a split of 2.3% from price and 0.7% from volume mix [11] - Gross margin improved by 220 basis points, resulting in 10.5% organic profit growth [6][10] - Free cash flow reached GBP 1.9 billion, with a reduction in working capital by 11 days [10][22] Business Line Data and Key Metrics Changes - Oral health grew by 7.9%, significantly outperforming the market, with strong growth in brands like Sensodyne and parodontax [13][20] - VMS (Vitamins, Minerals, and Supplements) grew by 1.9%, with strong performance outside the U.S. but impacted by a softer multivitamin category in North America [14] - OTC (Over-the-Counter) pain relief grew by 2.3%, with notable growth in Panadol and the launch of Voltaren patches [14][15] - Respiratory health declined by 1.9%, affected by a challenging consumer environment and a weaker cold and flu season [16] Market Data and Key Metrics Changes - North America experienced a 0.4% decline in organic revenue, with a split of 1% price increase and a 1.4% decline in volume mix [17] - EMEA and Latin America saw organic revenue increase by 4.7%, driven by price increases and resilient performance in oral health [19] - Asia Pacific reported a 5.2% organic revenue growth, with significant contributions from China and India [20] Company Strategy and Development Direction - The company is focused on three strategic priorities: delivering competitive growth, unlocking productivity gains, and embedding an agile culture [1][4] - Plans to evolve the operating model to drive growth and agility were announced, including the creation of new leadership roles and operating units [28][29] - The company aims to return North America to growth through targeted actions and investments in marketing and innovation [8][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in outperforming the market despite a challenging operating environment, with expectations for 2026 organic revenue growth in the range of 3%-5% [7][26] - The outlook for North America is cautiously optimistic, with plans to enhance market execution and innovation [7][32] - Management acknowledged the need for improved organic revenue performance and emphasized the focus on productivity to drive future growth [10][26] Other Important Information - The company allocated GBP 500 million for share buybacks in 2026 and proposed a final dividend of 4.9 pence, marking a 7.6% increase in total dividends for the year [6][25] - The new operating model is expected to deliver GBP 175 million-GBP 200 million in gross annualized savings, enhancing flexibility and agility [24] Q&A Session Summary Question: What are the expectations for organic revenue growth in 2026? - The company expects organic revenue growth to be in the range of 3%-5%, with a focus on returning North America to growth and continued strength in emerging markets [7][26] Question: How is the company addressing the challenges in North America? - The company is implementing a broader action plan, strengthening the North America team, and investing in capabilities to drive distribution and marketing effectiveness [32] Question: What are the key drivers of the productivity agenda? - Key drivers include reducing SKUs, optimizing supply chain efficiency, and leveraging automation and AI to enhance operational effectiveness [4][12]